We studied the metabolic pathways of dihydroxyphenylalanine (DOPA) and dopamine as well as the cardiovascular and renal responses to a single administration of DOPA (500 mg orally) in stable essential hypertension. We found that after DOPA, stable hypertensive patients compared with controls showed more blood pressure decrease without reflex tachycardia, had lower creatinine clearance but a higher fractional excretion of sodium, and had lower plasma renin activity at the height of DOPA action. Hypertensive patients also showed increased plasma DOPA, the ratio of plasma DOPA to dopamine, and the sum of plasma DOPA and 3-O-methyl-DOPA, as well as increased urinary 3-0-methyl-DOPA and the plasma and urine dopamine metabolites 3,4-dihydroxyphenylacetic acid and homovanillic acid. Finally, despite an augmented post-DOPA glomerular load of DOPA, the predominant source of urinary dopamine, the excretion rates of dopamine and its metabolites remained comparable in hypertensive patients to those in control subjects. These data suggest that, in stable hypertensive patients, exogenous DOPA is to a lesser degree decarboxylated to dopamine, which is more rapidly metabolized intraneuronally. Contrasting with this finding are the hyperdopaminergic features, such as hypernatriuresis with renin suppression and excessive blood pressure decline in the absence of reflex tachycardia. They may be due to an upregulation of renal, vascular, and brain dopaminergic receptors secondary to a preexisting dopaminergic deficiency in stable essential hypertension. {Hypertension 1992;19:634-638) KEY WORDS • DOPA • dopamine • essential hypertension T he possibility that dopamine, an essentially vasodilator and natriuretic catecholamine, may be involved in the pathogenesis of essential hypertension (EH) is still a controversial subject because of the very low plasma free dopamine concentrations and the heterogeneity of the EH syndrome.
T he possibility that dopamine, an essentially vasodilator and natriuretic catecholamine, may be involved in the pathogenesis of essential hypertension (EH) is still a controversial subject because of the very low plasma free dopamine concentrations and the heterogeneity of the EH syndrome. 1 Detection of dopaminergic abnormalities is also made difficult by the fact that dopamine, generated from 3,4-dihydroxyphenylalanine (DOPA) not only in the sympathetic nervous system but also in non-neuronal tissues, is rapidly converted to either 3,4-dihydroxyphenylacetic acid (DOPAC) or 3-methoxytyramine (3-MT) and subsequently to homovanillic acid (HVA). Previous studies have demonstrated an attenuated urinary dopamine response to salt in stable EH (s-EH) patients, 1 its probable cause suspected to be a deficient renal DOPA decarboxylation to dopamine. 2 This aspect was investigated by Aoki et al 3 in EH with an oral precursor load of DOPA in an attempt to at least partially reproduce patterns of defective renal dopamine generation from DOPA. However, the conclusions were based only on plasma DOPA and urinary dopamine measurements, without the determination of some intermediate steps between plasma DOPA and urinary dopamine, their respective metabolites, and blood pressure (BP) responses to exogenous DOPA. Moreover, the EH patients were defined only as normal and low renin EH, without respect to other BP characteristics (such as borderline and s-EH), which, in addition to salt sensitivity, 2 proved to be important determinants of the heterogeneity of dopaminergic involvement in EH. 1 We have demonstrated in a previous study 4 that it is possible to detect some hyperdopaminergic patterns in borderline EH patients with measurements of several intermediate steps after an exogenous DOPA-induced increase of circulating DOPA (including metabolites of DOPA, such as 3-O-methyl-DOPA, and of dopamine, such as dopamine sulfate, DOPAC, 3-MT, and HVA in plasma and urine) as well as of renal and vascular responses to dopamine generated from DOPA. Because s-EH patients are closest to those studied earlier, 1 -3 and in contrast to borderline EH characterized by an opposite (i.e., dopaminergic) defect, 2 we extended our investigation to s-EH patients with the oral DOPA test. Because these patients were generally older than the borderline EH patients studied previously, 4 we had to compare them with an older group of control subjects.
Methods
We followed 12 s-EH patients (nine men and three women) whose mean age (mean±SEM, 54.9 ±2.2 years) was matched with five control men (52.2±1.8 years). These EH patients were considered to be stable when their hypertension was consistently more than 160/95 mm Hg and their BP did not decrease (when medication had been stopped) to normotensive values after 4 days of bed rest. 3 They had been treated with all categories of antihypertensive drugs for up to 22 years. They stopped all medication at least 10 days (longer acting drugs, 3 weeks) before the examination. They received a diet containing 150 mmol/day Na + , 100 mmol K + , and 90 g/day protein, with citrus fruits, cereals, and coffee excluded for at least 3 days before the test. None of the women had taken oral contraceptives at any time. On the day preceding the test, a 24-hour urine sample was collected. Urinary Na + excretion in this sample was comparable in control subjects and s-EH patients (see Table 1 ), suggesting a similar state of sodium balance. After an overnight fast, the subjects arrived at the clinical center and assumed a supine position until the study was completed. At 8 AM, a heparin lock for blood collection was placed in the right antecubital vein, and baseline blood samples were taken at 8:30 AM (-30') and 9 AM (0'). At 9 AM, 500 mg DOPA (levodopalarodopa, Roche Laboratories, Nutley, N.J.) was administered orally, and consecutive blood samples were obtained at 60-minute intervals for the remainder of the study (60,120, and 180 minutes). Urine was collected at 60-minute intervals (hours 1, 2, and 3). At 9 AM and 10 AM, 250 ml tap water was administered orally. BP and pulse rate were monitored every 30 minutes before and after DOPA treatment, and body weight was measured before and after the test. This study was approved by the Clinical Research Institute of Montreal Ethics Committee, and subjects gave their informed consent. Blood samples collected in tubes were placed on ice and immediately centrifuged at 5,000g for 15 minutes at 4°C. Plasma and urine were poured into cooled plastic vials containing 0.5 mg/ml sodium metabisulfite as antioxidant, and vials were frozen and stored at -80°C until assay. All the methods of determination (radioenzymatic and high-performance liquid chromatography) were identical to those in our most recent study. 4 Because DOPA is immediately metabolized to 3-0-methyl-DOPA and the generated dopamine to either DOPAC or 3-MT and subsequently to HVA, these plasma and urinary metabolites served as indexes of DOPA metabolism, dopamine generation, and metabolism, respectively. The mean absolute values and their changes for control subjects and s-EH patients were analyzed by unpaired Student's / test. DOPA-induced modifications in each parameter containing two factors (time and the value change) were analyzed by two-way analysis of variance with repeated measures on one factor.
Results

Effect of DOPA on Blood Pressure, Pulse Rate, and Renal Responses
DOPA induced a significantly greater fall in systolic and diastolic BP in s-EH patients than in control subjects (Table 1 ). Unlike in s-EH patients, pulse rate increased significantly in control subjects after DOPA administration. DOPA induced significant increases in urinary volume and urinary sodium concentration in both control subjects and s-EH patients, but these hourly values were not different between the two groups. Nevertheless, the cumulative 3-hour urinary Na + excretion after DOPA was higher in s-EH patients than control subjects. Although there was no significant difference between baseline values and those after DOPA administration, creatinine clearance at hour 2 was significantly lower in s-EH patients than in control subjects. The fractional excretion of Na + , which increased after DOPA administration in both groups, was significantly greater 120 minutes after DOPA in s-EH patients than in control subjects. Plasma renin activity before and after DOPA administration was comparable, except for a lower value in s-EH patients 2 hours after DOPA.
• Plasma tyrosine decreased 2 hours after DOPA administration marginally in control subjects (from 7.1±0.7 to 6.5±1.4 ngjm\) but significantly in s-EH patients (from 6.8±0.6 to 4.5±0.4 /tg/ml; p<0.01) and remained suppressed 3 hours after DOPA. Plasma DOPA, 3-O-methyl-DOPA, free dopamine, dopamine sulfate, DOPAC, and HVA were considerably increased after DOPA administration, but only plasma DOPA, DOPAC (Figure 1) , and HVA were significantly higher in s-EH patients than in control subjects. Because DOPA is either decarboxylated to dopamine or metabolized to 3-O-methyl-DOPA, the increase of the sum of DOPA and 3-O-methyl-DOPA after DOPA administration represents an index of DOPA cumulation before the decarboxylation step. This index was higher in s-EH patients than in control subjects (p<0.02). The ratio of plasma DOPA to dopamine, an approximate index of DOPA decarboxylation, clearly increased after DOPA administration in both groups, being significantly higher in s-EH patients than in control subjects (Figure 1) . These data suggest a slower DOPA decarboxylation and an increased dopamine metabolism to DOPAC in s-EH patients than in control subjects.
Renal Events After DOPA Administration
The glomerular DOPA load was markedly augmented after DOPA administration, and this elevation was significantly greater in s-EH patients than in control subjects (Table 2) . DOPA, free dopamine, dopamine sulfate, 3-MT, and the ratio of urinary DOPA to dopamine were markedly augmented after DOPA treatment, but only the increases of 3-O-methyl-DOPA, DOPAC, and HVA were significantly higher in s-EH patients than in control subjects. The ratio of urinary dopamine and the DOPA load, which is higher as more DOPA is decarboxylated to dopamine, approximately doubled in both groups 60 minutes after DOPA administration; its mean basal and peak values were lower in s-EH patients than in control subjects, but neither achieved statistical significance.
Discussion
Considerable dopamine generation leading to natriuresis and decreased BP occurred after DOPA administration. These DOPA-induced renal (natriuresis) and cardiovascular (BP) responses were enhanced in s-EH patients despite comparable plasma and urinary free dopamine values in both these patients and control subjects. This is in accordance with previous reports of an augmented natriuretic reaction of EH patients to intravenously administered dopamine, 6 dopamine-1 agonist, 7 or a dopamine prodrug 8 attributed to an upregulation of dopaminergjc receptors. Paradoxically, plasma renin activity was depressed despite more natriuresis and lowered BP in s-EH patients but not in control subjects. The DOPAinduced reflex tachycardia of control subjects not materializing in s-EH patients despite their enhanced BP decrease suggests a peripheral sympathetic outflowsuppressing central action of DOPA (with dopamine receptors upregulated in s-EH?), which also may have been responsible for the decreased plasma renin activity in s-EH patients. This observation is reminiscent of a similar central DOPA action detected by measurement of sympathetic nerve activity after DOPA treatment in experimental hypertension, 9 but similar human observations are still lacking.
The suppression of tyrosine by DOPA administration appears to be a feedback effect on the main precursor of catecholamine synthesis. In contrast to borderline EH patients, in whom an escape from the inhibitory action appeared at hour 3 after DOPA, 4 this inhibition persisted and was more potent in s-EH patients than in control subjects. This may reflect a lower catecholamine turnover with less tyrosine supply for its neural uptake in s-EH patients compared with the opposite in borderline EH patients. Provided that there is no difference in intestinal absorption, decarboxylation and sulfoconjugation of DOPA between control subjects and s-EH patients, the higher plasma DOPA and DOPA-todopamine ratio, and a higher cumulation of DOPA and 3-0-methyl-DOPA after DOPA administration suggest a slower decarboxylation of DOPA to dopamine in s-EH patients. To what degree the decreased dopamine generation from DOPA occurred in neuronal and nonneuronal tissues can be only estimated. Because DOPAC generation requires not only DOPA decarboxylation to dopamine but also the action of monoamine oxidase, the sites of which are the mitochondria close to the vesicles of the nerve endings, we can indirectly conclude from the increase in DOPAC that an important decarboxylation of DOPA occurred in neural tissues. The monoamine oxidase action may be so rapid that no dopamine increase or even its decrease may occur after DOPA as previously observed. 10 Digestive organs (small intestine, liver, and stomach) and the kidney" contain aromatic L-amino acid decarboxylase (LAAD) (EC 4.1.1.28) and convert administered DOPA to dopamine, possibly also contributing to the observed differences. LAAD activity originating in neuronal and non-neuronal tissues can be found in human plasma. Because EH patients tend to have lower plasma LAAD levels than control subjects 12 and their values decrease with age, it is conceivable that s-EH patients have an overall diminished ability to decarboxylate DOPA. The resulting higher plasma DOPA and 3-Omethyl-DOPA after DOPA administration is followed by an increased glomerular DOPA load and higher urinary 3-O-methyl-DOPA excretion in s-EH patients. Despite increased glomerular DOPA load, there was, however, no more rise in urinary dopamine excretion, which would be expected after an augmented renal supply of the dopamine precursor. This suggests that relatively less dopamine is generated from DOPA entering the kidney in s-EH patients. The alternative possibility that more dopamine is metabolized to DOPAC and HVA, suggested by the heightened renal excretion of both dopamine metabolites (DOPAC and HVA) in s-EH patients, is less probable; both excessively increased in plasma and thus were increasingly cleared by the kidney.
The finding that the post-DOPA ratio of plasma DOPA to dopamine is higher in s-EH (unlike the ratio of urinary DOPA to dopamine, reflecting mostly nonneuronal decarboxylation) suggests distinct roles of the prerenal (predominantly neuronal) and renal (predominantly nonneuronal) LAAD activity in s-EH patients. Most recently, the finding of two different messenger RNAs for LAAD, one for neuronal and another for nonneuronal tissues, 13 is compatible with the notion that the overall decrease of plasma LAAD activity in EH 12 may, at least when DOPA is orally administered, predominantly affect the neuronal decarboxylation of DOPA. Genetic probes may become available in the future to study this important question.
In the dopamine actions, we have to distinguish between renal hemodynamic and natriferic tubular responses to dopamine. 7 The finding that the creatinine clearance of s-EH patients at the height of DOPAinduced dopamine generation was lower than that of control subjects, whereas the fractional Na + excretion of s-EH patients was higher (with baseline values of both being comparable), is compatible with an impaired renal hemodynamic but an even upregulated natriuretic (tubular) response to dopamine generated from DOPA. This resembles a similar observation made in response to exogenous dopamine in patients with renal diseases and moderate impairment of renal function.
14 An abnormal renal responsiveness to dopamine, conceivably even with normal renal functions, is compatible with Guyton's concept (Guyton et al 15 ) of the role of the kidney in perpetuating hypertension.
In conclusion, s-EH patients present an enhanced BP and natriuretic and plasma renin activity-suppressing responses to DOPA unaccounted for by increased dopamine generation from DOPA. This suggests dopamine receptor upregulation by a preexisting dopaminergic deficiency, particularly in the renal tubules. The lower plasma dopamine rise relative to DOPA and the increase of DOPA and its metabolite suggest that less dopamine generation from exogenous DOPA occurs in s-EH patients, in contrast to the opposite in borderline EH patients, who have an increased neuronal and extraneuronal generation of dopamine from administered DOPA. 4 Whether this represents in s-EH patients an intrinsic disorder or an acquired abnormality and to what degree it is attributable to differences in L -D O P A pharmacokinetics or its intraneuronal and extraneuronal decarboxylation to dopamine remains to be investigated.
